A recent phase 1, dose-escalation study demonstrated the safety and efficacy of cabozantinib plus nivolumab alone (cabo/nivo) or in combination with ipilimumab (cabo/nivo/ipi) for several genitourinary diseases, including metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Andrea Apolo, MD, and colleagues released a final data analysis of the study and 7 expansion cohorts, including overall response rate (ORR), progression-free survival, and overall survival results. ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
The primary end point was establishing the risk of relapse connected with both surgical approaches.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
